Real-world Health Outcomes in Canadian Patients Using Semaglutide

Semaglutide in Patients With Type 2 Diabetes: Real-world Analysis in the Canadian LMC Diabetes Registry: The SPARE Study

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are an injectable, non-insulin therapy for patients with type 2 diabetes (T2D). Semaglutide (Ozempic®) is the newest GLP-1 RA to become available in Canada in 2018, and is administered subcutaneously once-weekly. In clinical trials, semaglutide has been superior to placebo and other antihyperglycemic agents in HbA1c reduction and body weight loss. However, there is little real-world evidence available on the effectiveness of semaglutide in real-world clinical practice.

To better understand the effectiveness of semaglutide on clinical outcomes in a real-world setting, this retrospective cohort study will use the Canadian LMC Diabetes Registry to examine the effects of semaglutide on glycemic control, body weight, and other clinical outcomes in patients with T2D who initiate once-weekly semaglutide as part of usual clinical care in a diabetes specialist practice group in Canada.

Inclusion Criteria:

• First prescription for semaglutide between Feb 1 2018 and Feb 1 2019
• Age ≥ 18 years at medication index date
• Clinical diagnosis of type 2 diabetes for greater than six months
• ≥ one HbA1c measurement at baseline and at follow-up
• ≥ one follow-up visit post index date
• Informed consent for medical data to be used for research purposes

Exclusion Criteria:

• Clinical diagnosis of type 1 diabetes
• Recent eGFR <40 ml/min/1.73m2
• Documented history of bariatric surgery